If you have been reading about freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
Reconstitution is often performed with sterile water, buffer, or a water-miscible organic solvent, depending on solubility. The solvent should be added gently along the vial wall, and the solution mixed by gentle swirling rather than vigorous vortexing, which can cause foaming and surface denaturation. Some sequences require a small amount of base or acid to dissolve, followed by pH adjustment. Preparing a concentrated stock solution can simplify later dilution, but the stock itself may have limited stability. Records of solvent, concentration, and date support reproducibility.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
| Property | Value | Notes |
|---|---|---|
| Container material | Type I borosilicate glass or polypropylene | Low peptide adsorption; avoid untreated polystyrene for dilute solutions. |
| Headspace gas | Nitrogen or argon | Inert gas reduces oxidation for methionine- or cysteine-containing peptides. |
| Light exposure | Amber vial or foil wrap | Limits photodegradation of tryptophan, tyrosine, and phenylalanine residues. |
| Reconstitution solvent | Water, buffer, or water-miscible organic solvent | Choice depends on sequence charge and hydrophobicity; use highest available purity. |
| Aliquot size | Single-use portions | Minimizes warming and cooling cycles and cross-contamination between uses. |
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Moisture, oxygen, and light also affect peptide integrity. Lyophilized powders absorb water from the air, which can enable hydrolysis and conformational changes. Oxygen promotes oxidation of sensitive residues, so storage under inert gas or in sealed vials is common. Light exposure can cause photodegradation, particularly for peptides containing aromatic amino acids. Buffer choice and pH influence charge state and solubility; extremes of pH accelerate deamidation and hydrolysis. Adding stabilizers such as sugars or polyols can protect the peptide during freezing and drying. Optimal conditions are determined empirically for each peptide.
Peptides are short chains of amino acids that can undergo both chemical and physical degradation. Chemical pathways include hydrolysis of peptide bonds, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and isomerization of aspartate. Physical instability leads to aggregation, precipitation, or adsorption to surfaces. The rate of these processes depends on the peptide sequence, the formulation, and the storage environment. Because each peptide has a unique composition, no single storage condition applies to all peptides. Stability studies are therefore conducted to define suitable conditions for each specific molecule.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
=== When density varies due to both concentration and temperature === Density variation due to both concentration and temperature is an important field of study in double diffusive convection. If density changes due to both temperature and salinity are taken into account, then some more terms add to the Z-Component of momentum as follows:
HHV-6 re-activation causes severe disease in transplant recipients and can lead to graft rejection, often in consort with other betaherpesviruses. Likewise in HIV/AIDS, HHV-6 re-activations cause disseminated infections leading to end organ disease and death. Although up to 100% of the population are exposed (seropositive) to HHV-6, most by 3 years of age, there are rare cases of primary infections in adults. In the United States, these have been linked more with HHV-6a, which is thought to be more pathogenic and more neurotropic and has been linked to several central nervous system-related disorders. HHV-6 has been reported in multiple sclerosis patients and has been implicated as a co-factor in several other diseases, including chronic fatigue syndrome, AIDS, and temporal lobe epilepsy.
==== Multicore myopathy ==== Multicore myopathy also referred to as minicore myopathy, is associated with small areas of decreased oxidative activities, resulting in areas that appear in this histology as "cores". These appear through microscopy very similar to central core, however the cores are typically smaller in multicore myopathy. As with congenital fiber type disproportion, patients have a greater number of type 1 fibers. Overall, approximately half of diagnosed individuals report no progression of muscle weakness, while half report a very slow progression.
March 19: Law facilitating donations to public or private charitable organizations, particularly those focused on increasing birth rates and protecting children and war orphans. April 23: Decree implementing the law of April 23, 1919, establishing an eight-hour workday in hotels, restaurants, cafés, and other food service establishments in the Paris region. May 9: Decree modifying the statutes of the Comédie-Française: both principal and substitute members must include at least one woman in each group. June 1: Circular regulating prostitution among women. July 25: Decree on the regulation of films; women may sit on the commission that grants film distribution visas. August 9: Competitive exams for editorial and translator-editor positions in the central administration of commerce and industry are opened to women for a provisional period of three years. August 27: Competitive exams for editorial and calculation clerk positions in the central administration of the Ministry of Labor and Social Welfare are opened to female candidates. October 24: Law protecting breastfeeding women: needy mothers breastfeeding their infants receive special allowances during the first year. October 25: Law creating and organizing chambers of agriculture in each French department; women with agricultural professions (or who had such work during the war) may vote and be elected. 1920
Sources: en.wikipedia.org
The female lays three to seven eggs, which both sexes help to incubate. Its breeding range extends from central and western Alaska across northern Canada to Nova Scotia, and south throughout North America, into central Mexico and the Caribbean. It is a local breeder in Central America and is widely distributed throughout South America. Most birds breeding in Canada and the northern United States migrate south in the winter. It is an occasional vagrant to Western Europe. The American kestrel is often used in falconry, especially by beginners. Though not as strong a flyer as many other, larger falcons, proper training and weight control by the falconer can allow captive American kestrels to become effective hunters of birds in the size range of sparrows and starlings, with occasional success against birds up to approximately twice their own weight.
== Other media == A Borderlands film was released by Gearbox and Lionsgate in 2024, with Eli Roth as director. The film received negative reviews from critics and poor reception from fans. In April 2020, Gearbox announced it was developing a television series based on its Brothers in Arms series.
A Gewald aminothiophene synthesis between 4-nitrophenylacetone [5332-96-7] (1) and ethyl cyanoacetate [105-56-6] (2) in the presence of sulfur and triethylamine to give an aminothiophene [174072-89-0]. The amino group was protected with cathyl chloride to give the corresponding carbamate, [308831-93-8] (3). Alkylation with 2,6-Difluorobenzyl chloride [697-73-4] (4) gave [308831-94-9]. Next, a free-radical bromination gave [308831-95-0] (5). Displacement of the bromide with (2-methoxyethyl)(methyl)amine [38256-93-8] (6) and subsequent catalytic hydrogenation of the nitro group gave PC53388810 (7). The aniline was reacted with CDI, and the resulting imidazolide was further treated with methoxyamine [67-62-9] to give the urea [737789-92-3] (8). A cyclization reaction mediated by diethyl pyrocarbonate (DEPC) in the presence of 3-methoxy-6-aminopyridazine [7252-84-8] (9) followed by exposure to sodium methoxide generated thymine derivative [737789-61-6] (10). Quaternization of the basic amine with 1-chloroethyl chloroformate followed by displacement with dimethylamine completed the synthesis of relugolix (11).
=== Metabolic disorders === Preclinical evidence from animal models suggests that S. boulardii supplementation may reduce body weight in the context of type 2 diabetes; however, clinical evidence in humans is currently lacking. Additional studies in diet-induced obesity models further support these findings, showing that S. boulardii can attenuate weight gain, reduce food intake, and increase energy expenditure. These effects are accompanied by coordinated changes in gut microbiota composition, microbial metabolic activity, and host immune signaling, including reduced inflammatory pathways (e.g., TNFα/NF-κB) and shifts in metabolites linked to metabolic regulation, suggesting modulation of the gut–immune–metabolic axis.
== Signs and symptoms == Pain may be the first noticed symptom. People with lipodermatosclerosis have tapering of their legs above the ankles, forming a constricting band resembling an inverted champagne bottle. In addition, there may be brownish-red pigmentation and induration. Symptoms may also include swelling in feet and ankles, leathery skin, flaky skin, itchy skin, leg cramping, leg heaviness, leg swelling, leg tiredness, leg achiness, foot pain, slow healing wounds on legs and feet, bulging varicose veins, warmth in legs, redness in legs, and pain with prolonged standing.
Sources: en.wikipedia.org
== History == Dexamethasone was first synthesized by Philip Showalter Hench in 1957. It was introduced for medical use in 1958. On 16 June 2020, the RECOVERY Trial announced preliminary results stating that dexamethasone improves survival rates of hospitalized patients with COVID-19 receiving oxygen or on a ventilator. Benefits were only observed in patients requiring respiratory support; those who did not require breathing support saw a worse survival rate than the control group, although the difference may have been due to chance. A preprint containing the full dataset was published on 22 June 2020, and demand for dexamethasone surged after the publication of the preprint. The preliminary report was published in The New England Journal of Medicine on 18 July 2020. The final report was published in February 2021. The World Health Organization (WHO) states that dexamethasone should be reserved for seriously ill and critical patients receiving COVID-19 treatment in a hospital setting, and the WHO Director-General stated that "WHO emphasizes that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm." In July 2020, the WHO stated they were in the process of updating treatment guidelines to include dexamethasone or other steroids. In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19.
Mark (1943), former U.S. ambassador to Burundi J. Owen Zurhellen, Jr. (1943), first U.S. ambassador to Suriname Christian H. Armbruster (1944), member of the New York State Assembly and the New York State Senate Harold Brown (1945), U.S. secretary of defense and president of the California Institute of Technology Albert Burstein (1947), Democratic Party politician and former Majority leader of the New Jersey General Assembly Edward N. Costikyan (1947), Democratic Party politician and reformer who oversaw the dismantling of Tammany Hall; partner at Paul, Weiss, Rifkind, Wharton & Garrison Gardiner L. Tucker (1947), former director of IBM Research and assistant secretary of defense for System Analysis, assistant secretary general of NATO Jonathan Dean (1948), U.S. representative for Mutual and Balanced Force Reductions negotiations 1979–1981 Roy H. McVicker (1948), U.S. congressman for Colorado's 2nd congressional district Monteagle Stearns (1948), former U.S. ambassador to Ivory Coast and U.S. ambassador to Greece Eugene Rossides (1949), lobbyist, football player drafted by the New York Giants in 1949, founder of the American Hellenic Institute, former U.S. assistant secretary of the treasury Donald A. Beattie (1951), assistant secretary for Conservation and Solar Applications in the United States Department of Energy and assistant administrator of the Energy Research and Development Administration Lawrence Pezzullo (1951), former U.S. ambassador to Uruguay, Nicaragua, and special envoy to Haiti; executive director of Catholic Relief Services 1983–1992 Eric M.
=== 2006–2010 === In 2006, Sonic Healthcare acquired Central Queensland Pathology Laboratory (Mackay, Queensland) merging it with Sullivan Nicolaides Pathology, Muskogee Clinical Laboratory (Muskogee, Oklahoma, US), The Cognoscenti Health Institute (East Orlando, Florida, US), and Lookadoo Skyline Laboratories (Port St Lucie, Florida, US). Bioscientia Healthcare Group based in Ingelheim, Germany, August 2007. In 2007, the company acquired American Esoteric Laboratories (Tennessee and Texas), the remaining 18% of Clinical Pathology Laboratories, Mullins Pathology & Cytology Laboratory P.C., Augusta, Georgia, US, Sunrise Medical Laboratories, a full-service clinical reference laboratory servicing Long Island and the New York metropolitan area, and Woodbury Clinical Laboratory in Lebanon, Tennessee. That same year, in Europe, the Medica Laboratory Group, based in Zurich, Switzerland, the Bioscientia Healthcare Group in Ingelheim, Germany, and the remaining equity in the Schottdorf Group were acquired. In Australia, Sonic Healthcare acquired LifeCheck (Sydney, NSW), merging it into Lifescreen. In 2008, in the US, Sonic Healthcare acquired American Clinical Services (New Jersey) merging it with Sunrise Medical Laboratories, Clinical Laboratories of Hawaii, and Pan Pacific Pathologists (Hawaii). In Europe, it acquired Labor Prof. Krech (Switzerland) merging it into Medica, Labor 28 (Berlin, Germany), GLP Medical Group (Hamburg, Germany), and 100% ownership of IPN which in turn acquired the Gemini Medical Group.
=== μ-opioid receptors === In clinical trials, the MOR is the main target of opioid ligand binding. While binding of the opioid to the MOR typically causes analgesia, there can be instances where hyperalgesia occurs. It has been speculated that the opposite analgesic and hyperanalgesic effects are due to different isoforms of the receptor. The MOR is a G protein-coupled receptor with seven transmembrane domains. Variants of the receptor have been discovered and are due to alternative splicing mechanisms. A particular receptor variant, 6TM MOR, has been heavily studied because of its role in nociception. The 6TM MOR is missing residues in the N-terminal region which has implications for the extracellular tail and first transmembrane domain. This causes an excitatory effect compared to the inhibition in the normal seven transmembrane domain receptor because of differences in G-protein activation. Studies on mice have shown silencing of the 6TM MOR variant decreased morphine-induced hyperalgesia which suggested G-protein coupling in the 6TM isoform could be a factor in the development of OIH.
Sources: en.wikipedia.org
Dividing a stock into single-use portions usually reduces multiple thawing and refreezing events and lowers contamination risk. It also allows a needed amount to be removed without warming the entire supply.
Peptides can adsorb to some plastics and glass, especially at low concentrations, which reduces the measured amount in solution. Low-binding polypropylene tubes limit this loss and improve reproducibility.
Thawing on ice or in a cold water bath is generally preferred over rapid heating, which can accelerate degradation. Once thawed, the aliquot should be kept cold and used promptly rather than refrozen.
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.